In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BridgeBio Oncology Therapeutics, with a price target of $27.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Robert Burns has given his Buy rating due to a combination of factors related to BridgeBio Oncology Therapeutics’ promising preclinical data and strategic advancements. The company presented compelling preclinical results for its pan-KRAS inhibitor, BBO-11818, which demonstrated strong anti-tumor responses in various cancer models. This inhibitor targets both active and inactive forms of KRAS with high potency and selectivity, showing potential as both a monotherapy and in combination with other treatments.
Furthermore, BBO-11818, when combined with BBO-10203, significantly enhances efficacy by reducing tumor cell proliferation and increasing apoptosis in cancer models. The combination with anti-PD-1 treatment also resulted in complete tumor regressions, indicating a promising therapeutic strategy. The ongoing Phase 1 KONQUER-101 trial is expected to provide further data, potentially expanding the treatment’s applicability to other KRAS mutations. These factors collectively support the Buy rating and a 12-month price target of $27.
In another report released on October 24, Piper Sandler also maintained a Buy rating on the stock with a $21.00 price target.